APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug-Device Combination Products

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug-Device Combination Products Market Outlook and Growth Opportunities 2026

19 December 2025216 pages

Choose your research edition.

Industry ResearchDrug-Device Combination Products Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug-Device Combination Products Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Drug-Device Combination Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug-Device Combination Products Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug-Device Combination Products Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Drug-Device Combination Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug-Device Combination Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug-Device Combination Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug-Device Combination Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug-Device Combination Products market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug-Device Combination Products market include GSK, Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Boston Scientific, Abbott, Boehringer Ingelheim and Medtronic, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug-Device Combination Products market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug-Device Combination Products and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug-Device Combination Products revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug-Device Combination Products market.

Drug-Device Combination Products Segment by Company

GSK

Novo Nordisk

Eli Lilly

AstraZeneca

Sanofi

Boston Scientific

Abbott

Boehringer Ingelheim

Medtronic

Mylan

3M

Hisamitsu

Smith & Nephew

Molnlycke

Teleflex

BD

Lepu Medical

MicroPort

Terumo

B. Braun

Antares Pharma

Drug-Device Combination Products Segment by Type

Drug-Coated Device

Prefilled Drug Delivery Systems

Nebulizer and Inhaler

Transdermal Delivery System

Others

Drug-Device Combination Products Segment by Application

Hospital andClinic

Retail Pharmacies

Other

Drug-Device Combination Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug-Device Combination Products status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug-Device Combination Products key companies, revenue, market share, and recent developments.

3. To split the Drug-Device Combination Products breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug-Device Combination Products market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug-Device Combination Products significant trends, drivers, influence factors in global and regions.

6. To analyze Drug-Device Combination Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug-Device Combination Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug-Device Combination Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug-Device Combination Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug-Device Combination Products industry.

Chapter 3: Detailed analysis of Drug-Device Combination Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug-Device Combination Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug-Device Combination Products in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug-Device Combination Products Industry Trends Table 2. Drug-Device Combination Products Industry Drivers Table 3. Drug-Device Combination Products Industry Opportunities and Challenges Table 4. Drug-Device Combination Products Industry Restraints Table 5. Global Drug-Device Combination Products Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug-Device Combination Products Revenue Share by Company (2021-2026) Table 7. Global Drug-Device Combination Products Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug-Device Combination Products Key Company Manufacturing Base & Headquarters Table 9. Global Drug-Device Combination Products Company, Product Type & Application Table 10. Global Drug-Device Combination Products Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug-Device Combination Products by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drug-Coated Device Table 15. Significant Companies of Prefilled Drug Delivery Systems Table 16. Significant Companies of Nebulizer and Inhaler Table 17. Significant Companies of Transdermal Delivery System Table 18. Significant Companies of Others Table 19. Global Drug-Device Combination Products Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Drug-Device Combination Products Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Drug-Device Combination Products Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Drug-Device Combination Products Sales Value Share by Type (2021-2026) Table 23. Global Drug-Device Combination Products Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital andClinic Table 25. Significant Companies of Retail Pharmacies Table 26. Significant Companies of Other Table 27. Global Drug-Device Combination Products Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Drug-Device Combination Products Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Drug-Device Combination Products Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Drug-Device Combination Products Sales Value Share by Application (2021-2026) Table 31. Global Drug-Device Combination Products Sales Value Share by Application (2027-2032) Table 32. Global Drug-Device Combination Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Drug-Device Combination Products Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Drug-Device Combination Products Sales Value Share by Region (2021-2026) Table 35. Global Drug-Device Combination Products Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Drug-Device Combination Products Sales Value Share by Region (2027-2032) Table 37. Global Drug-Device Combination Products Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Drug-Device Combination Products Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Drug-Device Combination Products Sales Value Market Share by Country (2021-2026) Table 40. Global Drug-Device Combination Products Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Drug-Device Combination Products Sales Value Market Share by Country (2027-2032) Table 42. GSK Company Information Table 43. GSK Business Overview Table 44. GSK Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. GSK Drug-Device Combination Products Product Portfolio Table 46. GSK Recent Development Table 47. Novo Nordisk Company Information Table 48. Novo Nordisk Business Overview Table 49. Novo Nordisk Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novo Nordisk Drug-Device Combination Products Product Portfolio Table 51. Novo Nordisk Recent Development Table 52. Eli Lilly Company Information Table 53. Eli Lilly Business Overview Table 54. Eli Lilly Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Eli Lilly Drug-Device Combination Products Product Portfolio Table 56. Eli Lilly Recent Development Table 57. AstraZeneca Company Information Table 58. AstraZeneca Business Overview Table 59. AstraZeneca Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AstraZeneca Drug-Device Combination Products Product Portfolio Table 61. AstraZeneca Recent Development Table 62. Sanofi Company Information Table 63. Sanofi Business Overview Table 64. Sanofi Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sanofi Drug-Device Combination Products Product Portfolio Table 66. Sanofi Recent Development Table 67. Boston Scientific Company Information Table 68. Boston Scientific Business Overview Table 69. Boston Scientific Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Boston Scientific Drug-Device Combination Products Product Portfolio Table 71. Boston Scientific Recent Development Table 72. Abbott Company Information Table 73. Abbott Business Overview Table 74. Abbott Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Abbott Drug-Device Combination Products Product Portfolio Table 76. Abbott Recent Development Table 77. Boehringer Ingelheim Company Information Table 78. Boehringer Ingelheim Business Overview Table 79. Boehringer Ingelheim Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Boehringer Ingelheim Drug-Device Combination Products Product Portfolio Table 81. Boehringer Ingelheim Recent Development Table 82. Medtronic Company Information Table 83. Medtronic Business Overview Table 84. Medtronic Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Medtronic Drug-Device Combination Products Product Portfolio Table 86. Medtronic Recent Development Table 87. Mylan Company Information Table 88. Mylan Business Overview Table 89. Mylan Drug-Device Combination Products Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Mylan Drug-Device Combination Products Product Portfolio Table 91. Mylan Recent Development Table 92. 3M Company Information Table 93. 3M Business Overview Table 94. 3M Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. 3M Drug-Device Combination Products Product Portfolio Table 96. 3M Recent Development Table 97. Hisamitsu Company Information Table 98. Hisamitsu Business Overview Table 99. Hisamitsu Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Hisamitsu Drug-Device Combination Products Product Portfolio Table 101. Hisamitsu Recent Development Table 102. Smith & Nephew Company Information Table 103. Smith & Nephew Business Overview Table 104. Smith & Nephew Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Smith & Nephew Drug-Device Combination Products Product Portfolio Table 106. Smith & Nephew Recent Development Table 107. Molnlycke Company Information Table 108. Molnlycke Business Overview Table 109. Molnlycke Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Molnlycke Drug-Device Combination Products Product Portfolio Table 111. Molnlycke Recent Development Table 112. Teleflex Company Information Table 113. Teleflex Business Overview Table 114. Teleflex Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Teleflex Drug-Device Combination Products Product Portfolio Table 116. Teleflex Recent Development Table 117. BD Company Information Table 118. BD Business Overview Table 119. BD Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. BD Drug-Device Combination Products Product Portfolio Table 121. BD Recent Development Table 122. Lepu Medical Company Information Table 123. Lepu Medical Business Overview Table 124. Lepu Medical Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Lepu Medical Drug-Device Combination Products Product Portfolio Table 126. Lepu Medical Recent Development Table 127. MicroPort Company Information Table 128. MicroPort Business Overview Table 129. MicroPort Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. MicroPort Drug-Device Combination Products Product Portfolio Table 131. MicroPort Recent Development Table 132. Terumo Company Information Table 133. Terumo Business Overview Table 134. Terumo Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Terumo Drug-Device Combination Products Product Portfolio Table 136. Terumo Recent Development Table 137. B. Braun Company Information Table 138. B. Braun Business Overview Table 139. B. Braun Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. B. Braun Drug-Device Combination Products Product Portfolio Table 141. B. Braun Recent Development Table 142. Antares Pharma Company Information Table 143. Antares Pharma Business Overview Table 144. Antares Pharma Drug-Device Combination Products Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Antares Pharma Drug-Device Combination Products Product Portfolio Table 146. Antares Pharma Recent Development Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Drug-Device Combination Products Product Image Figure 2. Global Drug-Device Combination Products Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug-Device Combination Products Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug-Device Combination Products Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drug-Coated Device Image Figure 8. Prefilled Drug Delivery Systems Image Figure 9. Nebulizer and Inhaler Image Figure 10. Transdermal Delivery System Image Figure 11. Others Image Figure 12. Global Drug-Device Combination Products Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Drug-Device Combination Products Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Drug-Device Combination Products Sales Value Share by Type (2021-2032) Figure 15. Hospital andClinic Image Figure 16. Retail Pharmacies Image Figure 17. Other Image Figure 18. Global Drug-Device Combination Products Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Drug-Device Combination Products Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Drug-Device Combination Products Sales Value Share by Application (2021-2032) Figure 21. Global Drug-Device Combination Products Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Drug-Device Combination Products Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Drug-Device Combination Products Sales Value (2021-2032) & (US$ Million) Figure 24. North America Drug-Device Combination Products Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Drug-Device Combination Products Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Drug-Device Combination Products Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Drug-Device Combination Products Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Drug-Device Combination Products Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Drug-Device Combination Products Sales Value (2021-2032) & (US$ Million) Figure 30. South America Drug-Device Combination Products Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Drug-Device Combination Products Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Drug-Device Combination Products Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Drug-Device Combination Products Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Drug-Coated Device
  • Prefilled Drug Delivery Systems
  • Nebulizer and Inhaler
  • Transdermal Delivery System
  • Others
Applications
  • Hospital andClinic
  • Retail Pharmacies
  • Other
Companies covered
  • GSK
  • Novo Nordisk
  • Eli Lilly
  • AstraZeneca
  • Sanofi
  • Boston Scientific
  • Abbott
  • Boehringer Ingelheim
  • Medtronic
  • Mylan
  • 3M
  • Hisamitsu
  • Smith & Nephew
  • Molnlycke
  • Teleflex
  • BD
  • Lepu Medical
  • MicroPort
  • Terumo
  • B. Braun
  • Antares Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug-Device Combination Products Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug-Device Combination Products Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug-Device Combination Products Market Dynamics
  1. 2.1 Drug-Device Combination Products Industry Trends
  2. 2.2 Drug-Device Combination Products Industry Drivers
  3. 2.3 Drug-Device Combination Products Industry Opportunities and Challenges
  4. 2.4 Drug-Device Combination Products Industry Restraints
3 Drug-Device Combination Products Market by Company
  1. 3.1 Global Drug-Device Combination Products Company Revenue Ranking in 2025
  2. 3.2 Global Drug-Device Combination Products Revenue by Company (2021-2026)
  3. 3.3 Global Drug-Device Combination Products Company Ranking (2024-2026)
  4. 3.4 Global Drug-Device Combination Products Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug-Device Combination Products Company Product Type and Application
  6. 3.6 Global Drug-Device Combination Products Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug-Device Combination Products Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug-Device Combination Products Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug-Device Combination Products Market by Type
  1. 4.1 Drug-Device Combination Products Type Introduction
  2. 4.1.1 Drug-Coated Device
  3. 4.1.2 Prefilled Drug Delivery Systems
  4. 4.1.3 Nebulizer and Inhaler
  5. 4.1.4 Transdermal Delivery System
  6. 4.1.5 Others
  7. 4.2 Global Drug-Device Combination Products Sales Value by Type
  8. 4.2.1 Global Drug-Device Combination Products Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Drug-Device Combination Products Sales Value by Type (2021-2032)
  10. 4.2.3 Global Drug-Device Combination Products Sales Value Share by Type (2021-2032)
5 Drug-Device Combination Products Market by Application
  1. 5.1 Drug-Device Combination Products Application Introduction
  2. 5.1.1 Hospital andClinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Drug-Device Combination Products Sales Value by Application
  6. 5.2.1 Global Drug-Device Combination Products Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drug-Device Combination Products Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drug-Device Combination Products Sales Value Share by Application (2021-2032)
6 Drug-Device Combination Products Regional Value Analysis
  1. 6.1 Global Drug-Device Combination Products Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug-Device Combination Products Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug-Device Combination Products Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug-Device Combination Products Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug-Device Combination Products Sales Value (2021-2032)
  7. 6.3.2 North America Drug-Device Combination Products Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug-Device Combination Products Sales Value (2021-2032)
  10. 6.4.2 Europe Drug-Device Combination Products Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug-Device Combination Products Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug-Device Combination Products Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug-Device Combination Products Sales Value (2021-2032)
  16. 6.6.2 South America Drug-Device Combination Products Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug-Device Combination Products Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug-Device Combination Products Sales Value Share by Country, 2025 VS 2032
7 Drug-Device Combination Products Country-level Value Analysis
  1. 7.1 Global Drug-Device Combination Products Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug-Device Combination Products Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug-Device Combination Products Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug-Device Combination Products Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug-Device Combination Products Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug-Device Combination Products Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug-Device Combination Products Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Drug-Device Combination Products Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Drug-Device Combination Products Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Drug-Device Combination Products Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Drug-Device Combination Products Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Drug-Device Combination Products Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Boston Scientific
  32. 8.6.1 Boston Scientific Company Information
  33. 8.6.2 Boston Scientific Business Overview
  34. 8.6.3 Boston Scientific Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Boston Scientific Drug-Device Combination Products Product Portfolio
  36. 8.6.5 Boston Scientific Recent Developments
  37. 8.7 Abbott
  38. 8.7.1 Abbott Company Information
  39. 8.7.2 Abbott Business Overview
  40. 8.7.3 Abbott Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Abbott Drug-Device Combination Products Product Portfolio
  42. 8.7.5 Abbott Recent Developments
  43. 8.8 Boehringer Ingelheim
  44. 8.8.1 Boehringer Ingelheim Company Information
  45. 8.8.2 Boehringer Ingelheim Business Overview
  46. 8.8.3 Boehringer Ingelheim Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim Drug-Device Combination Products Product Portfolio
  48. 8.8.5 Boehringer Ingelheim Recent Developments
  49. 8.9 Medtronic
  50. 8.9.1 Medtronic Company Information
  51. 8.9.2 Medtronic Business Overview
  52. 8.9.3 Medtronic Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medtronic Drug-Device Combination Products Product Portfolio
  54. 8.9.5 Medtronic Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mylan Drug-Device Combination Products Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 3M
  62. 8.11.1 3M Company Information
  63. 8.11.2 3M Business Overview
  64. 8.11.3 3M Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  65. 8.11.4 3M Drug-Device Combination Products Product Portfolio
  66. 8.11.5 3M Recent Developments
  67. 8.12 Hisamitsu
  68. 8.12.1 Hisamitsu Company Information
  69. 8.12.2 Hisamitsu Business Overview
  70. 8.12.3 Hisamitsu Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hisamitsu Drug-Device Combination Products Product Portfolio
  72. 8.12.5 Hisamitsu Recent Developments
  73. 8.13 Smith & Nephew
  74. 8.13.1 Smith & Nephew Company Information
  75. 8.13.2 Smith & Nephew Business Overview
  76. 8.13.3 Smith & Nephew Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Smith & Nephew Drug-Device Combination Products Product Portfolio
  78. 8.13.5 Smith & Nephew Recent Developments
  79. 8.14 Molnlycke
  80. 8.14.1 Molnlycke Company Information
  81. 8.14.2 Molnlycke Business Overview
  82. 8.14.3 Molnlycke Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Molnlycke Drug-Device Combination Products Product Portfolio
  84. 8.14.5 Molnlycke Recent Developments
  85. 8.15 Teleflex
  86. 8.15.1 Teleflex Company Information
  87. 8.15.2 Teleflex Business Overview
  88. 8.15.3 Teleflex Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Teleflex Drug-Device Combination Products Product Portfolio
  90. 8.15.5 Teleflex Recent Developments
  91. 8.16 BD
  92. 8.16.1 BD Company Information
  93. 8.16.2 BD Business Overview
  94. 8.16.3 BD Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BD Drug-Device Combination Products Product Portfolio
  96. 8.16.5 BD Recent Developments
  97. 8.17 Lepu Medical
  98. 8.17.1 Lepu Medical Company Information
  99. 8.17.2 Lepu Medical Business Overview
  100. 8.17.3 Lepu Medical Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Lepu Medical Drug-Device Combination Products Product Portfolio
  102. 8.17.5 Lepu Medical Recent Developments
  103. 8.18 MicroPort
  104. 8.18.1 MicroPort Company Information
  105. 8.18.2 MicroPort Business Overview
  106. 8.18.3 MicroPort Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  107. 8.18.4 MicroPort Drug-Device Combination Products Product Portfolio
  108. 8.18.5 MicroPort Recent Developments
  109. 8.19 Terumo
  110. 8.19.1 Terumo Company Information
  111. 8.19.2 Terumo Business Overview
  112. 8.19.3 Terumo Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Terumo Drug-Device Combination Products Product Portfolio
  114. 8.19.5 Terumo Recent Developments
  115. 8.20 B. Braun
  116. 8.20.1 B. Braun Company Information
  117. 8.20.2 B. Braun Business Overview
  118. 8.20.3 B. Braun Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  119. 8.20.4 B. Braun Drug-Device Combination Products Product Portfolio
  120. 8.20.5 B. Braun Recent Developments
  121. 8.21 Antares Pharma
  122. 8.21.1 Antares Pharma Company Information
  123. 8.21.2 Antares Pharma Business Overview
  124. 8.21.3 Antares Pharma Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Antares Pharma Drug-Device Combination Products Product Portfolio
  126. 8.21.5 Antares Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst